AZD9496

• CAT Number: I002137
• CAS Number: 1639042-08-2
• Molecular Formula: C25H25F3N2O2
• Molecular Weight: 442.51
• Purity: ≥95%
• Synonyms: (E)-3-(3,5-difluoro-4-((1R,3R)-2-(2-fluoro-2-methylpropyl)-3-methyl-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indol-1-yl)phenyl)acrylic acid
• Target: Estrogen Receptor/ERR
• Solubility: DMSO: ≥ 104.5 mg/mL
• Storage: Store at -20°C
• IC50: 0.7 nM(Ki); 0.14 nM(ER downregulation cell IC50) [1]
• IUPAC Name: (E)-3-[3,5-difluoro-4-[(1R,3R)-2-(2-fluoro-2-methylpropyl)-3-methyl-1,3,4,9-tetrahydropyrido[3,4-b]indol-1-yl]phenyl]prop-2-enoic acid
• InChI: InChI=1S/C25H25F3N2O2/c1-14-10-17-16-6-4-5-7-20(16)29-23(17)24(30(14)13-25(2,3)28)22-18(26)11-15(12-19(22)27)8-9-21(31)32/h4-9,11-12,14,24,29H,10,13H2,1-3H3,(H,31,32)/b9-8+/t14-,24-/m1/s1
• InChIKey: DFBDRVGWBHBJNR-BBNFHIFMSA-N
• SMILES: C[C@@H]1CC2=C([C@H](N1CC(C)(C)F)C3=C(C=C(C=C3F)/C=C/C(=O)O)F)NC4=CC=CC=C2

AZD9496(CAT: I002137) is an investigational compound designed for advanced pharmaceutical research, primarily targeting hormone receptor-positive breast cancer. Acting as a potent and selective oral estrogen receptor (ER) antagonist and degrader, it disrupts estrogen-driven signaling pathways critical for tumor growth and survival. AZD9496 is particularly valuable in studying ER-positive breast cancers, including those resistant to traditional endocrine therapies. Its oral bioavailability and ability to degrade ERα make it a promising candidate for therapeutic development. With high specificity and efficacy, AZD9496 supports in vitro and in vivo studies, advancing research into innovative treatments for hormone-dependent malignancies.